Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on RYTM stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Whitney Ijem has given his Buy rating due to a combination of factors including Rhythm Pharmaceuticals’ strong performance in the second quarter of 2025, where the company exceeded topline expectations despite increased operational expenses. These expenses were primarily attributed to clinical trial costs, development activities, and marketing efforts, which are seen as strategic investments for future growth.
Additionally, the company is making significant progress in its launch readiness for setmelanotide in adult and pediatric endocrinology, with a focus on a specialty launch strategy. The management’s confidence in the potential of setmelanotide, particularly in the exploratory trial for Prader-Willi Syndrome (PWS), and the anticipation of future data readouts, further supports the positive outlook. The unchanged price target of $105 reflects the analyst’s confidence in the company’s strategic direction and growth potential.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.
RYTM’s price has also changed dramatically for the past six months – from $60.010 to $90.010, which is a 49.99% increase.